|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910457692103321 |
|
|
Titolo |
Systemic treatment of prostate cancer [[electronic resource] /] / edited by Alan Horwich |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Oxford ; ; New York, : Oxford University Press, 2010 |
|
|
|
|
|
|
|
ISBN |
|
0-19-174025-X |
0-19-960737-0 |
1-283-34833-0 |
9786613348333 |
0-19-157581-X |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (102 p.) |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Prostate - Cancer - Diagnosis |
Prostate - Cancer - Treatment |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Contents; Preface; Symbols and abbreviations; Contributors; 1 Biological principles of hormone therapy; 2 PSA as a marker of progression and response in advanced prostate cancer; 3 Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer; 4 Systemic treatment of recurrence after local therapies; 5 First-line hormone therapy for metastatic prostate cancer; 6 Second- and third-line hormone therapies; 7 Chemotherapy for metastatic prostate cancer; 8 The role of bisphosphonates in the systemic treatment of prostate cancer; 9 Systemic isotope therapy of bone metastasis |
10 Biological targets and new drug development for prostate cancerIndex; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Z |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine |
|
|
|
|